Turbine and Daiichi Sankyo have expanded their collaboration to support antibody-drug conjugate (ADC) discovery using computational modelling. 

The expansion follows the completion of an initial feasibility programme that evaluated Turbine’s predictive modelling capabilities for ADC research.

Under the expanded collaboration, Daiichi Sankyo will use Turbine’s virtual biology platform, vLab, to conduct Virtual Assays. These computational experiments simulate biological responses across multiple conditions and can be used to investigate complex biological processes at scale.

The collaboration will apply vLab to Daiichi Sankyo’s proprietary ADC programmes. The approach is intended to support the evaluation of different biological variables and provide data to guide decisions during the discovery process.

The initial feasibility programme evaluated the ability of Turbine’s modelling approach to generate insights relevant to ADC research and development. Following the programme, the companies agreed to extend the collaboration and apply the platform to Daiichi Sankyo’s ADC programmes.

ADC development involves evaluating factors such as payload selection, drug combinations, therapeutic indications and biomarker strategies. The growing use of new payload classes has also increased the number of biological variables that need to be considered during discovery.

Computational experiments can allow researchers to examine a wider range of conditions before selecting experiments for laboratory testing. Turbine’s vLab platform is designed to simulate biological experiments and generate data that can be used alongside laboratory results.

The collaboration will also use an iterative approach in which computational predictions are tested experimentally, with the resulting data used to improve subsequent modelling. This process is intended to support the identification and prioritisation of hypotheses and candidates for further investigation.

The companies will use the combined computational and experimental approach to support decision-making across ADC discovery and explore potential strategies for developing new cancer therapies.

 

Source: turbine.ai

Report Abuse